← All trials
NCT05823675
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 19, 2023
- Primary completion
- Oct 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Apr 21, 2023
- Last posted
- May 25, 2023
- Enrollment
- 44
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Biotech Pharmaceutical Co., Ltd.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.